Cleansing the body from the accumulated xenobiotics and excess biological compounds and metabolites is known as detoxification. Detoxification has been shown to be extremely beneficial as a preventive measure. Certain nutritional factors play extremely important roles in the proper functioning of the cellular cleansing processes. The body’s natural detoxifying ability will deteriorate if these nutrients are deficient or lacking at the cellular level. In addition, certain botanicals and botanical extracts have been shown to strengthen the cells and maximize the processes that are involved in detoxification reactions. 
The CLEARVITE Program is a Systemic Nutritional Support and Detoxification program. Each ingredient (reference 1) in this program has been investigated extensively for its effect and functionality in supporting biochemical pathways. CLEARVITE should be an integral part of any detoxification and treatment program for complex health issues. 

DIAGNOSTIC AND THERAPEUTIC
The CLEARVITE Detoxification works through an Elimination/Provocation program that is diagnostic and therapeutic:

Diagnostic

• Identifies Food Sensitivities

  • If a patient feels better food sensitivities are causing the problems.

• Gut Inflammation/Infection

  • If a person doesn’t feel better they probably have GI infection/inflammation and need further lab analysis.

Therapeutic

• Decrease exposure to antigens

• Increase lipase pathways

• Clear liver

• Repair gut

• Balance sugar

NUTRITIONAL SUPPORT
CLEARVITE is designed to provide the necessary nutritional compounds and botanical extracts that have been recognized to be pivotal in the body’s natural ability to neutralize and expel toxins. It is an excellent source of hypoallergenic protein, in addition to nutrients that promote the breakdown and utilization of fat; herbal compounds that stimulate the formation of bile, bile secretions and elimination; and numerous nutritional cofactors and botanical extracts that support phase I and II liver detoxification reactions. 

DETOXIFICATION
Most hormones and xenobiotics, including over the counter and prescription drugs, can very seldom be eliminated from the body unchanged. These must be subjected to numerous chemical changes (detoxification) in order to be eliminated from the body. The major detoxification reactions take place in the liver. The potential for metabolic disorders increase when detoxification pathways are impaired. The liver must convert the toxins from fat soluble to water soluble in order to be eliminated. After conversion the hormones and xenobiotics are delivered to the gallbladder to be excreted with bile to be eliminated in the stool/feces. Gastrointestinal problems will increase environmental sensitivities and if uncorrected leads to a never ending struggle with allergies and food sensitivities. Any physical, biological, or biochemical factor that interferes with the free flow of bile can have adverse effects on the natural detoxification processes of the body. 

CLEARVITE is most effective when used according to a specific dietary Elimination/Provocation plan. The accumulated toxins in the body are mostly imbedded in different tissues, especially in fat and connective tissue. To remove these toxins effectively from the system, the detoxification pathways should always be supported and reinforced. The system should be supplied with the precursors of the compounds required for the detoxification reactions. Complimentary supplements in the specific protocol provide the cofactors of the enzyme systems that catalyze these reactions and will maximize the detoxification reactions. After the detoxification reactions are restored, the accumulated toxins will enter into the excretion routes and be released from the body.

Specific indications for program
4R program

• Remove – includes destroying pathogenic bacteria, yeast, Candida or parasites

• Replace – includes supporting the digestive system with enzymes such as hydrochloric acid, pancreatic enzymes and biliary support

• Re-inoculate - involves replenishing the gastrointestinal tract with friendly bacteria

• Repair – includes proper nutritional support to repair the gastrointestinal lining

Bacterial, Candida, Yeast Overgrowth

• Small bowel bacterial overgrowth is a result of abnormal motility in the small intestine. Undigested food is not swept out because the contractions are too weak or disorganized, and the bacteria grow out of control.

Anemia/Inflammation

• If you have limited to no success with taking supplements or medications, you may have sub-clinical anemia. This would stop your body from responding.

• It is not possible to improve health problems if a person is anemic. If anemic, they will not be able to deliver oxygen to the mitochondria for ATP production via oxidative phosphorylation and then become dependant upon glycolosis for energy production. Glycolosis is an inefficient ATP producing pathway and will place great demands on the blood sugar/adrenal stabilizing system. Anemia must be ruled out first using Functional analysis of a Comprehensive Wellness Panel.

• Using iron supplements to support anemia when gut inflammation is present will accelerate free radical damage in the body.

Insulin Resistance

• Sugar cravings after meals

• Fatigue after meals

• Cravings for sugar

• Inability to lose weight

• Constant hunger

• Fatigue after meals

• Migrating aches and pains

NOTE: Flax Seed Oil should not be taken with Insulin Resistance. The inflammation occurring, contributing to the Insulin Resistance will drive your body into PG2 inflammatory pathways. How would you know if this is occurring? If you feel better after taking an aspirin, it is likely you have an active PG2 inflammatory pathway.

Gastrointestinal Problems

Dysbiosis—is the state of disordered microbial ecology that causes disease. It may exist in the mouth, gastrointestinal tract or vaginal cavity. A common cause of bacterial or fungal dysbiosis is repeated or long term use of antibiotics. Antibiotics kill both the bacteria you to kill and the friendly bacteria in the intestine and vagina. This leaves these areas open to be colonized by yeast, unfriendly bacteria and parasites. In dysbiosis, unfriendly organisms induce disease by altering the nutrition, the immune response and causing inflammation and irritation in the intestines and vagina.
Putrefaction
Putrefaction– results from diets high in fat and meat and low in fiber. Altered body structure causes a failure to properly chew the food and insufficient digestive chemistry. This leaves chunks of food and meat in the digestive tract which only the surface area can be affected by the diminished digestive chemistry. The chunks then provide a food source for bacteria, which produce ammonia increasing fecal pH. Increased pH raises your risk for colon and breast cancer. The change in colon pH can first be observed with the onset of cancer sores in the mouth. Enzyme activity changes from constructive to destructive causing arthritis and degenerative joint disease. Estrogen scheduled for elimination is re-activated raising blood estrogen levels.
Fermentation Excess
Fermentation Excess— excess carbohydrate consumption and intolerance to sugars induce excess bacterial fermentation usually resulting from small bowel bacterial overgrowth. The by-product of fermentation is gas. Abdominal bloating or distention, flatulence, diarrhea, constipation and feelings of malaise are commonly described. In small bowel bacterial overgrowth, degradation of intestinal brush-border and pancreatic enzymes by bacterial protease may cause maldigestion. Fecal short chain fatty acids may be elevated. People with fermentations excess are usually intolerant of soluble fiber supplements and often benefit from antimicrobials and reduction of carbohydrate consumption.

DEFICIENCY
Deficiency - Exposure to antibiotics or a diet depleted of soluble fiber may create a deficiency of normal fecal flora, including Bifidobacteria, Lactobacillus and E. coli. Direct evidence of this condition is seen in stool cultures when concentrations of any of these organisms are reduced. This condition has been described in patients with irritable bowel syndrome and food intolerance.
Deficiency and putrefaction Dysbiosis often occur together and respond to the same treatment. Probiotic supplementation as well as fructooligosaccharides is often helpful in reestablishing a normal flora.

SENSITIZATION
Abnormal immune responses to components of the normal indigenous intestinal microflora may contribute to the onset of inflammatory bowel disease, arthritic conditions, connective tissue disorders, scleroderma and other skin conditions such as psoriasis or acne. Endotoxins may activate the alternative complement pathway, and sensitization may complement fermentation excess. Similar treatment may benefit both conditions.

CLEARVITE REFERENCE INFO (1)
Bach AC and Babyan VK. Medium-chain triglycerides: An update. Am J Clin Nutr 36,950-962, 1982.
Seatib TB, et al. Thermic effect of medium-chain and long-chain triglycerides in man. Am J Clin Nutr 44, 630-634, 1986.
Graf E. Antioxidant potential for ferulic acid. Free Had Biol Med 13,435-448. 1992.
Scott BC, et al. Evaluation of the antioxidant actions of ferulic acid and catachins. Free Rad Res Comma 19, 241-253, 1993.
Takemoto T, et al. Clinical trial of Hi-Z pills on gastrointestinal symptoms at 375 hospitals. Shiyaku To Rinsho 26, 2-27, 1977
Sasagwa T, et al. Clinical studies on gamma-oryzanol in the treatment of gastro-enero neurosis- Basic Pharmacol Ther 4, 588-591,1980.
Minakuchi C, et al. Clinical effects of gamma-oryzanol on gastric system complaints. Shiyaka To Rhinsho 25, 29-33,1976.
Noda H et al. Biotin production by bifidobacteria. J Nutr Sci Vitaminol 40,181-188,1994.
Klimberg V et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer Julyl;66(l):62-68, 1990.
Noyar CM, et al. A double-blind placebo-controlled pilot study of glutamine therapy for abnormal intestinal permeability in patients with AIDS. Am J Gastroenterol 93(6), 972-975, 1998.
Evans MA and Shronts EP. Intestinal fuels: glutamine, short-chain fatty acids, and dietary fiber. J Amer Diet Assoc 92. 1239-1246,1992
Shahani KM and Ayebo AD. Role of dietary lactobacilli its gastrointestinal microecology. Am J Clin Nutr 33, 2448-2457,1980.
Shahani Km and Friend BA. Nutritional and therapeutic aspects of lactobacilli. J Appl Nutr 36, 125-152,1984
Barefoot SF et al. Detection and activity of lacticin B, a bactcriocin produced by Lactobacillus Acidophilus. Appl Environ Microbiol 45, 1808-1815, 1983.
Tomontatsu H. Health effects of oligosaccharides, Food Tech October, 61-65.1994. 
Gibson GR, et al. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenserology 108, 975-982,1995.
PDR for Herbal Medicines 1st Ed. Medical Economics Co. Montvale, New Jersey 1998.
Ferrandiz ML, et al. Anti-inflammatory activity and inhibition of arachadonic acid metabolism by flavonoids, Agents Action 32,283-287,1991.
Middleton E and Drzewieki G. Flavonoid inhibition of human basophil histamine release stimulated by various agents. Biochem Pharmacol 33, 3333-3338, 1984.
Facino RM, et al. Free radicals scavenging action and anti-enzyme activities of procyanidines from Vitus vinifera: A mechanism for their capillary protective action. Arzeim Forsch 44, 592-60, 1994.
Lindahl M, et al. Flavonoids as phospholipase A2 inhibitors: Importance of their structure for selective inhibition of group II phospholipase A2. Inflammation 21(3):347-356, 1997.
Naasauto G et al. Effects of silbinion on biliary lipid composition. Experimental and
clinical sundy. J Hepatol 1991;12:290-295.
Wagnar H. Antihepatotoxic flavonioids. In: Cody Middleton H, Harbourne JB, eds, Plant flavonoids in biology and medicine: biochemical, pharmacological, and structure- activity relationships. New York, NY: Alan H. Lisa, 1986:p545-558
Adzet T. Polyphenolic compounds with biological activity and pharmacological activity. Herbal Spices Medicinal Plants 1986;l:167-184
Hikino H, Kiso Y. Wagner FL Antihepatotoxic actions of flavanolignans from Silybum marianum fruits. Plant Medica 1984;50:248-250.
Fiebrich F. Koch H. Siymarin, an inhibitor of prostaglandin synthetase. Experentia
1979;35:l50-152.
Feibrich F, Koch H. Silymarin an inhitor of lipoxygenase. Experentia 1979;35:148-150.
Palasciano G, Protinacasa P, et al. The effect of silymarin on plasma levels of
malonadialdehyde in patients receiving long-term treatment of psychotropic drugs. Cur Ther Res 1994;55:537-545.

Sonnenbicher J, Goldberg M, Hane L. et al. Stimulatory effect of silibinin on the DNA synthesis in partially hepatectomized rat livers. Non-responsive in hepatoma and other malignant cell lines. Biochem Pharma 1986;35:538-541.